Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eight Products Enter US FDA’s Opioid Challenge

Executive Summary

After spending the past six months receiving and reviewing hundreds of product applications, US FDA has decided to select eight promising devices and diagnostics to help tackle the opioid crisis.

You may also be interested in...

Gottlieb Points To Breakthrough And Localized Therapy Devices For Non-Opioid Pain Control

In one of his last public appearances as US FDA commissioner, Scott Gottlieb identified new opioid-alternative medtech products in the regulatory pipeline that provide distraction therapy and thermal management for pain relief. The agency chief also pointed to old-school devices that provide localized delivery of analgesic drugs as effective opioid-substitute or opioid-reducing devices.

‘State Of HHS’ Speech Highlights Price Transparency, Disaster Response

US Secretary of Health & Human Services Alex Azar discussed the move toward value-based health care, as well as HHS’s role in disaster response, as part of an annual "State of the Department" speech. The speech is tied to the release of HHS’s annual report.

AdvaMed Urges Medicare Commission To Emphasize Devices As Opioid Alternatives

In a statement to the Medicare Payment Advisory Commission, the medtech industry group bemoans the lack of consideration for medical device alternatives to opioids in treating pain management. The group says the commission should factor in such alternative treatments, per the SUPPORT Act, in their recommendations to Congress in March.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts